Literature DB >> 10525090

Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2.

K Sawada1, T Terada, H Saito, Y Hashimoto, K I Inui.   

Abstract

Peptide transporters (PEPT1 and PEPT2) in epithelia play an important role in the absorption of small peptides and peptide-like drugs. Recently, it was demonstrated that various nonpeptidic compounds can be transported by these transporters. In the present study, we focused on the L-amino acid ester compounds and examined the mechanisms of their interaction with rat PEPTs (rPEPTs) using stable transfectants. Valacyclovir, the L-valyl ester prodrug of the antiherpetic agent acyclovir, competitively inhibited [(14)C]glycylsarcosine uptake in the rPEPT1- or rPEPT2-expressing cells. Dixon plot analyses showed that the inhibition constant (K(i)) values of valacyclovir were 2.7 and 0.22 mM for rPEPT1 and rPEPT2, respectively, suggesting that rPEPT2 had higher affinity for this agent. Various L-valine alkyl esters significantly inhibited [(14)C]glycylsarcosine uptake. L-Valine methyl ester (Val-OMe) competitively inhibited [(14)C]glycylsarcosine uptake with K(i) values of 3.6 and 0.83 mM for rPEPT1 and rPEPT2, respectively, indicating that Val-OMe is also a high-affinity substrate for rPEPT2. Val-OMe had a trans-stimulation effect on [(14)C]glycylsarcosine efflux from both transfectants, suggesting the translocation of L-valine methyl ester via rPEPTs. Val-OMe showed the most potent inhibitory effect among the several L-amino acid methyl esters examined. We conclude that Val-OMe, as well as valacyclovir, could be recognized and transported by rPEPT1 and rPEPT2 and that these L-valyl esters showed higher affinity for rPEPT2 as do most substrates of these transporters. Our results suggest that L-valine is a desirable L-amino acid for the esterification of poorly permeable drugs to enhance their oral bioavailability targeting intestinal PEPT1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525090

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Theoretical predictions of drug absorption in drug discovery and development.

Authors:  Patric Stenberg; Christel A S Bergström; Kristina Luthman; Per Artursson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

3.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

4.  Computational modelling of H+-coupled peptide transport via human PEPT1.

Authors:  Megumi Irie; Tomohiro Terada; Toshiya Katsura; Satoshi Matsuoka; Ken-ichi Inui
Journal:  J Physiol       Date:  2005-03-31       Impact factor: 5.182

5.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

6.  Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+).

Authors:  Nagavedi S Umapathy; Vadivel Ganapathy; Malliga E Ganapathy
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.580

Review 7.  Recent advances in understanding prodrug transport through the SLC15 family of proton-coupled transporters.

Authors:  Gurdeep S Minhas; Simon Newstead
Journal:  Biochem Soc Trans       Date:  2020-04-29       Impact factor: 5.407

8.  Acetylation turns leucine into a drug by membrane transporter switching.

Authors:  Grant C Churchill; Michael Strupp; Cailley Factor; Tatiana Bremova-Ertl; Mallory Factor; Marc C Patterson; Frances M Platt; Antony Galione
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.